Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

PURPOSE: We present the results of a post hoc tumor tissue analysis from the phase 3 MILO/ENGOT-ov11 study (NCT01849874). PATIENTS AND METHODS: Mutation/copy-number analysis was performed on tissue obtained pre-randomization. The Kaplan–Meier method was used to estimate progression-free survival (PF...

Descripción completa

Detalles Bibliográficos
Autores principales: Grisham, Rachel N., Vergote, Ignace, Banerjee, Susana, Drill, Esther, Kalbacher, Elsa, Mirza, Mansoor Raza, Romero, Ignacio, Vuylsteke, Peter, Coleman, Robert L., Hilpert, Felix, Oza, Amit M., Westermann, Anneke, Oehler, Martin K., Pignata, Sandro, Aghajanian, Carol, Colombo, Nicoletta, Cibula, David, Moore, Kathleen N., del Campo, Josep M., Berger, Regina, Marth, Christian, Sehouli, Jalid, O'Malley, David M., Churruca, Cristina, Kristensen, Gunnar, Clamp, Andrew, Farley, John, Iyer, Gopa, Ray-Coquard, Isabelle, Monk, Bradley J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570675/
https://www.ncbi.nlm.nih.gov/pubmed/37581616
http://dx.doi.org/10.1158/1078-0432.CCR-23-0621

Ejemplares similares

Ejemplares similares